Cargando…
Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) u...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033676/ https://www.ncbi.nlm.nih.gov/pubmed/7981084 |
_version_ | 1782136889271123968 |
---|---|
author | Molto, L. Alvarez-Mon, M. Carballido, J. Manzano, L. Guillen, C. Prieto, A. Olivier, C. Rodriguez-Zapata, M. |
author_facet | Molto, L. Alvarez-Mon, M. Carballido, J. Manzano, L. Guillen, C. Prieto, A. Olivier, C. Rodriguez-Zapata, M. |
author_sort | Molto, L. |
collection | PubMed |
description | The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-alpha 2b and 3 and 6 months after finishing the instillation treatment. The [3H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P < 0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P > 0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-alpha 2b in the follow-up examinations 3 and 6 months after treatment (P < 0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-alpha 2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease. |
format | Text |
id | pubmed-2033676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20336762009-09-10 Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Molto, L. Alvarez-Mon, M. Carballido, J. Manzano, L. Guillen, C. Prieto, A. Olivier, C. Rodriguez-Zapata, M. Br J Cancer Research Article The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-alpha 2b and 3 and 6 months after finishing the instillation treatment. The [3H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P < 0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P > 0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-alpha 2b in the follow-up examinations 3 and 6 months after treatment (P < 0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-alpha 2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease. Nature Publishing Group 1994-12 /pmc/articles/PMC2033676/ /pubmed/7981084 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Molto, L. Alvarez-Mon, M. Carballido, J. Manzano, L. Guillen, C. Prieto, A. Olivier, C. Rodriguez-Zapata, M. Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title_full | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title_fullStr | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title_full_unstemmed | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title_short | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. |
title_sort | intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic t-cell activation. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033676/ https://www.ncbi.nlm.nih.gov/pubmed/7981084 |
work_keys_str_mv | AT moltol intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT alvarezmonm intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT carballidoj intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT manzanol intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT guillenc intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT prietoa intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT olivierc intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation AT rodriguezzapatam intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation |